Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Lysogene S.A. is a biotechnology company focused on developing gene therapies for rare neurological diseases, particularly targeting conditions like GM1 gangliosidosis. The company operates primarily in France and has a unique competitive advantage through its proprietary AAV-based gene therapy platform, which aims to address unmet medical needs in the central nervous system.
Lysogene's business model is centered on developing and commercializing innovative gene therapies, leveraging its proprietary technology to create treatments for rare diseases. The company aims to monetize its pipeline through partnerships, research grants, and eventual product sales, although it currently lacks revenue generation.
Clinical trial results for GM1 gangliosidosis therapy
Partnership announcements with larger pharmaceutical companies
Regulatory approvals for its gene therapy products
Funding rounds or grants received for R&D
Regulatory changes impacting gene therapy approvals
Technological disruption in gene therapy methodologies
Emergence of new gene therapies from competitors
Potential for larger pharmaceutical companies to dominate the market
High cash burn rate with no current revenue streams
Potential liquidity issues if funding is not secured
low - The demand for biotechnology products is less sensitive to economic cycles, as they often address critical health needs regardless of economic conditions.
High interest rates could increase the cost of financing for ongoing clinical trials and R&D, impacting the company's cash flow and valuation multiples.
minimal - The company currently has a negative debt/equity ratio, indicating it is not reliant on credit markets for financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has exhibited significant volatility, with a 1-year return of -80.2%.